1. Scrip
  2. >>R&D
  3. >>Clinical Trials

UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay

 
• By Ayisha Sharma

UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.  

UCB Celebrates Win In Psoriatic Arthritis Even As Regulatory Wait Is Prolonged • Source: Alamy

UCB S.A.’s Bimzelx has met its primary and secondary endpoints in a Phase III psoriatic arthritis study, BE OPTIMAL, bouncing back from frustrations over the US Food and Drug Administration’s delay in approving the drug for psoriasis. (Also see "UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug" - Scrip, 18 October, 2021.)

In August, Bimzelx (bimekizumab) gained EU and UK approval for psoriasis, its lead indication where it is touted as a blockbuster. (Also see "UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster" - Scrip, 30 July, 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D